In contrast, a recently reported G protein biased GLP-1R agonist, with a reduced ability to recruit arrestin compared to other FDA-approved GLP-1R agonists, displayed potent long term glycemic benefits in a mouse model of type 2 diabetes without the commonly associated nausea that limits the dose of this class of treatment [18]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.